INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 171 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is 0.70 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $2,518,000 | -49.2% | 40,000 | 0.0% | 0.35% | -35.0% |
Q4 2019 | $4,957,000 | +56.9% | 40,000 | -16.0% | 0.54% | +37.1% |
Q3 2019 | $3,159,000 | +5.6% | 47,600 | +26.6% | 0.40% | +20.0% |
Q2 2019 | $2,992,000 | +33.0% | 37,600 | -2.3% | 0.33% | +8.6% |
Q4 2017 | $2,249,000 | -3.1% | 38,500 | -3.8% | 0.30% | +2.7% |
Q3 2017 | $2,322,000 | +537.9% | 40,000 | +1229.8% | 0.30% | +469.2% |
Q2 2017 | $364,000 | -89.3% | 3,008 | -90.0% | 0.05% | -90.3% |
Q1 2017 | $3,393,000 | +56.1% | 30,000 | +50.0% | 0.54% | +28.8% |
Q4 2016 | $2,173,000 | -99.9% | 20,000 | +100.0% | 0.42% | +59.8% |
Q3 2016 | $1,645,900,000 | +42287.3% | 10,000 | -61.5% | 0.26% | -55.5% |
Q4 2015 | $3,883,000 | -26.8% | 26,000 | -18.8% | 0.59% | -30.6% |
Q3 2015 | $5,308,000 | -8.4% | 32,000 | +33.3% | 0.85% | +21.6% |
Q2 2015 | $5,793,000 | -10.7% | 24,000 | +4.3% | 0.70% | -36.4% |
Q1 2015 | $6,486,000 | +89.0% | 23,000 | +4.5% | 1.09% | +9.9% |
Q4 2014 | $3,432,000 | -22.0% | 22,000 | +18.3% | 1.00% | -22.8% |
Q3 2014 | $4,402,000 | – | 18,600 | – | 1.29% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |